IMMUSE Therapeutics develops immune-based therapies that target both tumor cells and immune cells within the tumor microenvironment, enhancing the efficacy of cancer treatment. This dual-targeting approach aims to increase tumor cell toxicity while boosting the activity of immune cells, improving patient outcomes in immune-related diseases.
Funding
$11.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail due to the tumor microenvironment's suppression of the immune system and the tumor cells' resistance to therapies. This necessitates treatments that can simultaneously target both the tumor cells and the immune cells within the tumor microenvironment to improve patient outcomes.
Solution
IMMUSE Therapeutics is developing immune-based therapeutics designed to target both tumor cells and immune cells within the tumor microenvironment. This dual-targeting approach aims to enhance the efficacy of cancer treatment by increasing tumor cell toxicity while simultaneously boosting the activity of immune cells. By modulating the tumor microenvironment, IMMUSE's therapies seek to overcome resistance mechanisms and improve patient outcomes in immune-related diseases. The company focuses on developing novel immunotherapies that can effectively stimulate the immune system to recognize and eliminate cancer cells.
Target Audience
The primary target audience includes patients with cancers that are resistant to current treatments, as well as oncologists and researchers seeking more effective immunotherapeutic options.
Features
- Dual-targeting mechanism: Targets both tumor cells and immune cells within the tumor microenvironment.
- Immuno-oncology approach: Enhances the body's natural defenses to fight cancer.
- Focus on modulating the tumor microenvironment to overcome resistance.